Our capabilities in Complex Injectables include developing and manufacturing products with complex active pharmaceutical ingredients (APIs), advanced formulations, specialized routes of administration, and drug-device combinations.
With an expertise in complex injectable technologies, we work with liposomes, nanoparticles, nanosuspensions, nanoemulsions, microspheres, peptides, and complex APIs under GMP-compliant manufacturing conditions.
Our portfolio includes a range of advanced injectable formulations such as liposomal products, nanoparticle and nanosuspension-based systems, nanoemulsions, and microsphere-based injectables. These technologies are designed to address formulation and delivery challenges associated with complex molecules, biologics, and poorly soluble drugs.
Complex injectable technologies offer several advantages over conventional drug delivery systems, such as-
Advanced delivery platforms such as suspensions and lipid-based nanoparticles also support improved bioavailability, stability, and long-acting drug delivery.
We are striving to develop high-quality, scalable, and reliable injectable solutions that address evolving therapeutic and patient needs across global markets.
| S.NO |
|---|
| 1 |
| 2 |
| 3 |
| 4 |
| 5 |
| 6 |
| S.NO | Product Name | Dosage Form | Strength |
|---|---|---|---|
| 1 | Amphotericin – B Liposomal | Lyophilized liposomal powder for injection | 50mg/vial |
| 2 | Albumin bound Paclitaxel nanoparticle | Lyophilized nanoparticle for injection | 100mg/vial |
| 3 | PEGASPARAGASE | Liquid injection & lyophilized injection | 3750 IU/vial |
| 4 | Leuprolite Acetate for depot suspension | Microsphere for injection (Lyophilizate for suspension for infusion) | 3.75mg/vial, 7.5mg/vial, 11.25 mg/vial |
| 5 | Octreotide | Microsphere for injection (Lyophilizate for suspension for infusion) | 10mg/vial, 20mg/vial, 30mg/vial |
| 6 | Bupivacaine Liposomal Injectable Suspension | Liposome for injection | 133mg/vial & 266mg/vial |